Analytical Data
-
Gene name
ELOA
- Application
-
Alternative Names
ELOA；TCEB3；Elongin-A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q14241
-
Expression Region
1-798aa
-
AA Sequence
MHGGRSCGPR TRREPSSGEE AAPVTAMAAE SALQVVEKLQ ARLAANPDPK KLLKYLKKLS TLPITVDILA ETGVGKTVNS LRKHEHVGSF ARDLVAQWKK LVPVERNAEP DEQDFEKSNS RKRPRDALQK EEEMEGDYQE TWKATGSRSY SPDHRQKKHR KLSELERPHK VSHGHERRDE RKRCHRMSPT YSSDPESSDY GHVQSPPSCT SPHQMYVDHY RSLEEDQEPI VSHQKPGKGH SNAFQDRLGA SQERHLGEPH GKGVVSQNKE HKSSHKDKRP VDAKSDEKAS VVSREKSHKA LSKEENRRPP SGDNAREKPP SSGVKKEKDR EGSSLKKKCL PPSEAASDNH LKKPKHRDPE KAKLDKSKQG LDSFDTGKGA GDLLPKVKEK GSNNLKTPEG KVKTNLDRKS LGSLPKVEET DMEDEFEQPT MSFESYLSYD QPRKKKKKIV KTSATALGDK GLKKNDSKST GKNLDSVQKL PKVNKTKSEK PAGADLAKLR KVPDVLPVLP DLPLPAIQAN YRPLPSLELI SSFQPKRKAF SSPQEEEEAG FTGRRMNSKM QVYSGSKCAY LPKMMTLHQQ CIRVLKNNID SIFEVGGVPY SVLEPVLERC TPDQLYRIEE YNHVLIEETD QLWKVHCHRD FKEERPEEYE SWREMYLRLQ DAREQRLRVL TKNIQFAHAN KPKGRQAKMA FVNSVAKPPR DVRRRQEKFG TGGAAVPEKI KIKPAPYPMG SSHASASSIS FNPSPEEPAY DGPSTSSAHL APVVSSTVSY DPRKPTVKKI APMMAKTIKA FKNRFSRR
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ELOA (Eloctate) is a recombinant protein that serves as a long-acting factor VIII replacement therapy for the treatment of hemophilia A, a genetic disorder characterized by deficient levels of clotting factor VIII, leading to excessive bleeding. The research surrounding ELOA emerged from the need for more effective and longer-lasting therapeutic options that could improve the quality of life for individuals with this condition. Traditional treatments often required frequent infusions, which posed challenges for patient adherence and overall management of hemophilia. In contrast, ELOA utilizes advanced protein engineering techniques to extend its half-life, reducing the frequency of administration while maintaining effective hemostatic control. Clinical studies have demonstrated that ELOA significantly reduces bleeding episodes and enhances the overall safety profile compared to conventional factor VIII therapies. Furthermore, ongoing research aims to optimize ELOA's delivery methods and assess its long-term efficacy and safety in diverse patient populations. The development of ELOA represents a significant advancement in the management of hemophilia A, providing patients with more convenient and effective treatment options. This innovative approach not only addresses the immediate need for better therapies but also reflects the broader trend in biopharmaceuticals to leverage recombinant technologies to enhance therapeutic outcomes in chronic conditions.
